Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Non-Current Liabilities: 2017-2024

Historic Total Non-Current Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $508.0 million.

  • Arcus Biosciences' Total Non-Current Liabilities fell 35.56% to $386.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $386.0 million, marking a year-over-year decrease of 35.56%. This contributed to the annual value of $508.0 million for FY2024, which is 3.46% up from last year.
  • As of FY2024, Arcus Biosciences' Total Non-Current Liabilities stood at $508.0 million, which was up 3.46% from $491.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Total Non-Current Liabilities registered a high of $628.4 million during FY2021, and its lowest value of $269.4 million during FY2020.
  • Over the past 3 years, Arcus Biosciences' median Total Non-Current Liabilities value was $503.0 million (recorded in 2022), while the average stood at $500.7 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 600.55% in 2020, then declined by 19.96% in 2022.
  • Yearly analysis of 5 years shows Arcus Biosciences' Total Non-Current Liabilities stood at $269.4 million in 2020, then skyrocketed by 133.24% to $628.4 million in 2021, then declined by 19.96% to $503.0 million in 2022, then declined by 2.39% to $491.0 million in 2023, then grew by 3.46% to $508.0 million in 2024.